...
首页> 外文期刊>Oncology reports >CHAF1B promotes proliferation and reduces apoptosis in 95-D lung cancer cells and predicts a poor prognosis in non-small cell lung cancer
【24h】

CHAF1B promotes proliferation and reduces apoptosis in 95-D lung cancer cells and predicts a poor prognosis in non-small cell lung cancer

机译:CHAF1B促进增殖并减少95-D肺癌细胞中的细胞凋亡,并预测非小细胞肺癌的预后差

获取原文
获取原文并翻译 | 示例
           

摘要

Chromatin assembly factor 1 subunit B (CHAF1B) participates in DNA synthesis and repair. High CHAF1B expression has been associated with a poor prognosis in several types of cancers. However, no study has evaluated the clinical significance and biological function of CHAF1B in non-small cell lung cancer (NSCLC). In the present study, we aimed to investigate CHAF1B expression and its role in NSCLC. In the present study, it was revealed that CHAF1B was highly expressed in NSCLC lung tissues and 95-D cells. Kaplan-Meier survival analysis indicated that high CHAF1B expression in tumour tissue was associated with poor clinical outcomes in NSCLC patients. Multivariate Cox analyses revealed that lymph node metastasis, tumour-node-metastasis (TNM) stage and CHAF1B expression were independent prognostic factors in NSCLC patients. Moreover, CHAF1B knockdown in 95-D cells markedly inhibited tumour proliferation, reduced colony formation, induced cell cycle arrest and promoted apoptosis. In vivo studies demonstrated that CHAF1B knockdown inhibited the growth of transplanted tumours. Furthermore, our results revealed that the mechanism by which CHAF1B induced apoptosis was mediated by the activation of the p53-dependent apoptotic signalling pathway (BAK/Bcl-2/caspase-3) in 95-D cells. These data indicated that CHAF1B plays an important role in tumourigenesis and may be a therapeutic molecular target to counter NSCLC progression.
机译:染色质组合因子1亚基B(CHAF1B)参与DNA合成和修复。高Chaf1b表达与几种类型的癌症预后差有关。然而,没有评估Chaf1B在非小细胞肺癌(NSCLC)中的临床意义和生物学功能。在本研究中,我们旨在调查Chaf1B表达及其在NSCLC中的作用。在本研究中,揭示了CHAF1B在NSCLC肺组织和95-D细胞中高度表达。 Kaplan-Meier存活分析表明,NSCLC患者的肿瘤组织中的高Chaf1B表达与患者临床结果不良有关。多变量COX分析显示,淋巴结转移,肿瘤 - 节点转移(TNM)阶段和CHAF1B表达是NSCLC患者的独立预后因素。此外,在95-D细胞中的CHAF1B敲低明显抑制肿瘤增殖,降低的菌落形成,诱导细胞周期停滞和促进凋亡。体内研究表明,CHAF1B敲低抑制了移植肿瘤的生长。此外,我们的结果表明,CHAF1B诱导的细胞凋亡的机制通过在95-D细胞中激活P53依赖性凋亡信号通路(Bak / Bcl-2 / caspase-3)来介导。这些数据表明,CHAF1B在肿瘤内发挥着重要作用,并且可以是对抗NSCLC进展的治疗分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号